G
Gerald J. Beck
Researcher at National Institutes of Health
Publications - 4
Citations - 679
Gerald J. Beck is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Renal function & Randomized controlled trial. The author has an hindex of 3, co-authored 4 publications receiving 640 citations. Previous affiliations of Gerald J. Beck include Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Dietary Protein Restriction and the Progression of Chronic Renal Disease What Have All of the Results of the MDRD Study Shown
Andrew S. Levey,Tom Greene,Gerald J. Beck,Arlene W. Caggiula,John W. Kusek,Lawrence G. Hunsicker,Saulo Klahr +6 more
TL;DR: The balance of evidence is more consistent with the hypothesis of a beneficial effect of protein restriction than with the contrary hypothesis of no beneficial effect, and the authors suggest that physicians incorporate the results of these secondary analyses into their interpretation of the findings of the MDRD Study.
Journal ArticleDOI
Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.
Saulo Klahr,Julia A. Breyer,Gerald J. Beck,Vincent W. Dennis,Judith A. Hartman,David M. Roth,Theodore I. Steinman,Shin Ru Wang,Monica E. Yamamoto +8 more
TL;DR: Lower protein intake, but not prescription of the keto acid-amino acid supplement, was marginally associated with a slower progression of renal disease, and the rate of decline was faster in participants with ADPKD than in persons with other diagnoses.
Journal ArticleDOI
Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study.
James A. Delmez,Guofen Yan,James Bailey,Gerald J. Beck,Srinivasan Beddhu,Alfred K. Cheung,George A. Kaysen,Andrew S. Levey,Mark J. Sarnak,Steve J. Schwab +9 more
TL;DR: High flux was associated with decreased CBVD mortality in those without known CBVD at baseline and those on hemodialysis therapy for longer than 3.7 years, strengthening, but not proving, the hypothesis that high-flux treatment may attenuate the death rate from vascular disease.
Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel Approach to Guide Renal Dose Adjustments
Britt B. Newsome,Joachim H. Ix,Hocine Tighiouart,Mark J. Sarnak,Andrew S. Levey,Gerald J. Beck,Geoffrey A. Block,Maria Cristina Comelli +7 more
TL;DR: The KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) and the Multi-Ethnic Study of Atherosclerosis [published online ahead of print January 2, 2013].